Cynata Therapeutics has met the clinical endpoints of a Phase 1 trial of its Cymerus mesenchymal stem cell (MSC) product candidate in people with steroid-resistant acute graft-versus-host disease (GvHD). The biotech company reported it had achieved a world first with the trial completion.
Cynata Therapeutics’ market-disruptive regenerative medicines complete world-first trial
Quick facts: Cynata Therapeutics Ltd
Price: 1.06 AUD
Market Cap: $124.15 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE